1	Full title of manuscript: Prevalence and spectrum of germline BRCA1 and BRCA2 mutations in
2	multiethnic cohort of breast cancer patients in Brunei Darussalam
3	
4	Short title of manuscript: BRCA1 and BRCA2 mutations in Brunei breast cancer patients
5	
6	Siti Nur Idayu Matusin², Nuramalina Mumin¹, Hazirah Zainal Abidin³, Fatin Nurizzati Mohd Jaya⁴, Lu Zen
7	Huat ¹ , Mas Rina Wati Haji Abdul Hamid ^{1*}
8	
9	¹ Pengiran Anak Puteri Rashidah Sa'adatul Bolkiah (PAPRSB) Institute of Health Sciences, Universiti Brunei
10	Darussalam, Negara Brunei Darussalam
11	
12	² Halalan Thayyiban Research Centre, Universiti Islam Sultan Sharif Ali, Jalan Tutong, Sinaut TB1741,
13	Negara Brunei Darussalam
14	
15	³ Ministry of Health, Commonwealth Drive, BB3910, Negara Brunei Darussalam
16	
17	⁴ ICC, AstraZeneca, Gaithersburg, MD, 20878, United States of America
18	* Corresponding author
19	E-mail: rina.hamid@ubd.edu.bn
20	
21	Author contributions
22	Conceptualised the original project: MRWHAH. Designed the experiments: MRWHAH, NM and SNIM.
23	Performed the experiments: SNIM, NM, HZA and FNMJ. Analysed the data: SNIM and LZH. Contributed

reagents/materials/samples/analysis tools: MRWHAH, LZH, SNIM, NM, HZA and FNMJ. Wrote the paper:
 SNIM. Reviewed the paper: MRWHAH

26

27 Abstract

28 This is the first genetic study of its kind in Brunei Darussalam. BRCA1 and BRCA2 genes are the most 29 well-known and well described predictors of hereditary breast cancer due to their clinical importance. 30 This study aimed to identify the prevalence and mutation spectrum of the BRCA1 and BRCA2 germline 31 mutations among 120 unselected series of Brunei breast cancer patients. We screened the entire 32 coding region of BRCA1 and BRCA2 gene using Sanger sequencing and next-generation sequencing methods, and identified three pathogenic and one likely pathogenic mutations in the BRCA2 gene. Of 33 34 the 120 patients, 6 (5%) were BRCA2 carriers which confirm that BRCA2 carriers are more common in 35 the Asian population compared to the Caucasian population. One BRCA2 mutation observed only in the 36 Chinese ethnicity of the Brunei breast cancer population contributes to the probability of the mutation being a founder effect in the Southern Chinese population. Brunei BRCA2 carriers were more likely to 37 38 have a positive family history of breast and/or ovarian cancers and have more than one family members 39 in the first-degree relatives diagnosed with breast cancer.

40

41 Introduction

Breast cancer is the most common cancer affecting women worldwide with varying incidence rates across the world [1]. Among the breast cancer risk factors, genetic predisposition confers the highest risk in breast cancer progression [2]. About 5-10% of breast cancers are inherited with approximately 30% of the inherited breast cancers were attributed to germline mutations in high penetrance breast cancer susceptibility genes, Breast Cancer susceptibility genes type 1 (*BRCA1*) [3]and Breast Cancer

susceptibility genes type 2 (*BRCA2*) [4]. *BRCA1* and *BRCA2* are tumour suppressor genes (TSGs) that
function by suppressing the growth of tumour cells via multiple DNA damage and repair pathways in the
cells [5-10]. Notably, the BRCA1 protein is multi-functional as it also regulates cell cycle through a
number of mechanisms [5,6,8,10-15].

51 BRCA1 and BRCA2 germline mutation carriers had an increased cumulative risk of 72% and 69%, 52 respectively to develop breast cancer by 80 years old [16]. BRCA1 and BRCA2 carriers would also have an 53 increased risk of developing ovarian, prostate, and pancreatic cancers [16]. Breast cancer patients who 54 inherit germline mutations in these genes, in particular BRCA1 carriers, are commonly associated with 55 triple negative breast cancer (TNBC), diagnosed at an early age of onset (<40 years), diagnosed with 56 bilateral breast cancer, having family history of breast and/or ovarian cancers in the first- and second-57 degree relatives, and having an ovarian cancer [17-21]. The discovery of these two genes being linked to 58 breast and ovarian cancers has led to the increased importance of genetic testing where continuous 59 research and development had ultimately resulted in BRCA1 and BRCA2 genetic tests available at a more 60 affordable cost and with a higher sensitivity and specificity [22]. Moreover, increased awareness on 61 available personalised treatment for affected patients such as olaparib, an oral poly ADP ribose 62 polymerase (PARP) inhibitor, which has been shown to provide a significant benefit over standard 63 therapy among the BRCA mutation-carrier patients [23-24], has led to the increasing demand for rapid 64 BRCA testing preferably at the first diagnosis [22]. This rapid increase caused pressure for diagnostic 65 laboratories to provide a genetic test with a shorter turnaround time [22]. The two most commonly 66 used platform for DNA sequencing are Sanger sequencing and Next-generation sequencing (NGS). 67 Although NGS has largely overtaken Sanger sequencing due to its cost-effective ability in screening a 68 larger set of samples in parallel and simultaneous screening of multiple cancer susceptibility genes in 69 one sample, Sanger sequencing is still used in laboratories today when the main objective is to screen a 70 single gene only.

71 Brunei Darussalam is a small country (5,765 sq km) on the Borneo Island, located in the South-72 east Asia (SEA) region, bordering the South China Sea and East Malaysia [25]. The population is 73 estimated over 400,000, comprises 66% Malay, 10% Chinese, 3% other indigenous and 21% other ethnic 74 groups [25]. Breast cancer was one of the top three leading causes of cancer mortality among women in 75 Brunei Darussalam with an incidence rate (age-standardized rate [ASR]) of 55.9 per 100,000 women 76 which is the second highest among countries in the SEA region, but considerably lower compared to the 77 Western Europe (ASR, 90.7) [1,26]. Notably, the incidence rate of breast cancer in Brunei varies by 78 ethnicity, with the highest rate observed in Chinese (ASR, 60.4) [27], followed by Malays (ASR, 48.1) [27], 79 and Others (ASR, 12.3) [28]. There has not been any formal study conducted on finding the contribution 80 of genetic and non-genetic factors in the rising incidence of breast cancer in Brunei. Therefore, 81 studying various aspects of breast cancer in the Brunei patients could help to understand and determine 82 the probable cause that leads to the rise in the incidence of the disease in the population, and in 83 planning a better health care for the Brunei population. The contribution of genetics in breast cancer 84 specifically in the involvement of susceptibility genes has been continuously researched on in the 85 Western and developed Asian countries resulting in many reports on the spectrum of variants within the susceptibility genes from all over the world. In the SEA region, the mutation spectrum of BRCA1 and 86 87 BRCA2 genes in breast cancer has been studied in Singaporean [18,19,29-31], Malaysian [21,32-37], 88 Filipino [38,39], Vietnamese [40,41], Thai [42,43], and Indonesian [44,45] populations leading to the 89 discovery of novel pathogenic variants from different ethnicities, suggesting the mutation spectrum of 90 the BRCA1 and BRCA2 genes are still understudied. Furthermore, a number of the variants identified in 91 the SEA breast cancer populations has also been found in other populations such as the African, 92 European and American suggesting that they are not specific to the reported population, implying the 93 genetic heterogeneity and randomness of the mutations. Interestingly, most of the variants identified in 94 the breast cancer population in East Malaysia which is also located on the Borneo Island [33] were not

95 identified in the West Malaysia population suggesting a difference in population genetics between East96 and West Malaysia.

97 Some of the variants identified in the Filipino breast cancer population who mostly were a combination of Malay and other population ancestry have also been proposed to be founder mutations 98 99 due to the shared haplotype markers [39]. Currently, there are no genetic mutation data that report on 100 the frequency of any genes related to breast cancer in Bruneian patients with or without family history. 101 Thus, genetic contribution in breast cancer and other related cancers in Bruneian population remains 102 uninvestigated. In this study, we investigated a population-based unselected series of Brunei breast 103 cancer patients to determine the prevalence and spectrum of BRCA1 and BRCA2 mutations using Sanger 104 and next-generation sequencing methods, and assess their association with sociodemographic, 105 clinicopathological, and family history characteristics of the population.

106

107 Materials and methods

108 Study population

109 The study population includes unselected incident and prevalent breast cancer patients seen from 18th May 2012 until 30th January 2013, and from 23rd May 2016 until 19th November 2018 at The Brunei 110 111 Cancer Centre (TBCC), Pantai Jerudong Specialist Centre (PJSC), the only cancer referral hospital in 112 Negara Brunei Darussalam. Terminally-ill patients were excluded from the study. Among approximately 113 567 patients attending clinics during this period of time, a total of 164 patients were approached and 114 explained about the study. Patient information sheet was provided and 121 patients consented as the 115 final study participants. All study participants signed informed consent document. Peripheral blood 116 samples and demographic and family history data were collected from the consenting patients. One 117 patient was later excluded due to insufficient DNA sample to complete the BRCA1 and BRCA2 mutation

analysis. Finally, 120 patients were included for the final analysis. Retrospective review of the study

119 participants' medical and histopathology records was conducted at TBCC with authorized permission

120 from relevant authorities from 1st November 2018 to 9th January 2019. The records were available in

121 the form of hard printed copy. The study was approved by the Brunei Darussalam Ministry of Health's

- 122 Medical and Health Research & Ethics Committee (MHREC).
- 123

124 BRCA1 and BRCA2 mutational screening

125 S1 Fig shows a flow chart of the strategy used to detect mutations in the BRCA1 and BRCA2 genes in the

study population. The samples from the first 66 study participants (henceforth referred to as Batch 1)

127 were analysed by Sanger sequencing while the samples from the last 54 study participants (henceforth

referred to as Batch 2) were sequenced by next-generation sequencing (NGS).

129

130 Sanger sequencing

131 Samples sequenced using Sanger sequencing utilised two workflows, PCR amplified with designed

primers, and PCR amplified using EasySeq[™] PCR Plates for *BRCA1/2* Sequencing (Nimagen, The

133 Netherlands).

In the first workflow, the gDNA extracted using Wizard Genomic DNA purification kit (Promega)
was amplified using AmpliTaq[®] 360 DNA Polymerase kit (Applied Biosystems) prior to sequencing. The
details of the primers and PCR conditions used in this study have been described elsewhere[46-48]. The
PCR products were resolved onto 1% agarose gel for evaluation of successful amplifications without
contamination. The remaining PCR products were then purified using QIAGEN QIAquick[®] PCR
Purification Kit.

140 In the second workflow, the gDNA extracted was amplified using the EasySeq[™] PCR Plates for 141 BRCA1/2 Sequencing (Nimagen, The Netherlands) following the manufacturer's protocol. The plate was 142 used for sequencing to screen for mutations in the complete coding region including ±50bp up- and 143 downstream of each BRCA1 and BRCA2 genes' coding exon. All of the primers in the columns were tailed 144 with universal tails – forward primers with -21M13 (5'-TGTAAAACGACGGCCAGT-3') and reverse primers 145 with M13Rev (5'-CAGGAAACAGCTATGACC-3'). PCR products from columns 1-10 were purified via ethanol/sodium acetate precipitation, and the pellets were resuspended with sterile water. 146 147 The purified PCR products from both workflows were used as the template for the Sanger sequencing reactions following the BigDye Terminator® v3.1 Cycle Sequencing Kit protocol (Applied 148 149 Biosystems, USA). The sequencing products were purified using the Axygen AxyPrep[™] Mag Dye Clean 150 Up Kit. BRCA1 and BRCA2 Sanger sequencing was performed using the ABI 3500 Genetic Analyzer 151 (Applied Biosystems, USA). The sequence data collected were processed and analysed using the 3500 152 Sequencing Analysis Software v5.2. Purified PCR products from the first workflow were sent for Sanger 153 sequencing (First BASE Laboratories, Malaysia). 154

155 Next-generation sequencing (NGS)

156 The DNA samples sequenced by NGS were outsourced to Cancer Research Malaysia (CRM) for *BRCA1*,

157 BRCA2, TP53, and PALB2 targeted panel sequencing. The HBOC_4_v2 gene panel used was developed

158 by CRM and the University of Melbourne and was used to screen for coding exons ±2 bp intronic

159 sequence of the BRCA1 (NM_007294.3), BRCA2 (NM_000059.3), PALB2 (NM_024675.3), and TP53

160 (NM_000546.4) genes. Bioinformatic analysis was performed by CRM and the variant results excluding

161 neutral polymorphisms were delivered upon completion.

163 **Bioinformatic analysis**

164 Sanger sequencing data obtained using Sequencing Analysis Software v5.2 and from First BASE 165 Laboratories were aligned to the reference sequences of the gene obtained from the NCBI GenBank 166 (BRCA1 NCBI RefSeg = NG 005905.2 and BRCA2 NCBI RefSeg = NG 012772.1) and nucleotide database 167 (BRCA1NCBI RefSeq = NM 007294.3 and BRCA2 NCBI RefSeq = NM 000059.3) using Variant Reporter Software v1.0 (Applied Biosystems, USA). All variants identified were annotated using the same 168 169 software. 170 For samples sequenced by NGS, although CRM have analysed and validated the results, the data 171 were re-analysed as neutral polymorphisms were not included in the provided results. The attainment of these results ensures the generation of a complete genetic variation profile for the patients. 172 173 Integrative Genomics Viewer (IGV) v2.5.2 (Broad Institute) was used to view the binary files provided by 174 CRM. The data were analysed using the public server at usegalaxy.eu [49]. Variants were called using 175 varscan (Galaxy Version 2.4.2) and bcftools call (Galaxy Version 1.9+galaxy 1). The data generated by 176 bcftools call were filtered using VCFfilter. All variants identified from NGS were annotated using the SNPeff Eff tool (Galaxy Version 4.3+T.galaxy1). 177 All variants identified from Sanger sequencing and NGS were annotated according to the 178 179 nomenclature used by the Human Genome Variation Society (HGVS) recommendation guidelines, using 180 the A of the ATG translation initiation codon as nucleotide +1. All identified missense variants were 181 analysed in silico using SIFT, PolyPhen-2, CADD, FATHMM-MKL, and DANN to predict the effect of amino acid substitution. Each prediction tool scored the missense variant as damaging or benign/neutral. All 182 183 variants identified in this study were also checked against the NCBI ClinVar, Varsome, and population frequency databases (gnomAD and 1000 genome). 184 185 All variants identified in this study, underwent thorough assessment and review of available

185 All variants identified in this study, underwent thorough assessment and review of available
 186 evidence (e.g. database information, and *in silico* predictions) following the American College of Medical

187 Genetics and Genomics and the Association for Molecular Pathology (ACMG) standards and guidelines 188 for the interpretation of sequence variants [50] to arrive at a final variant classification of either 189 pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, and benign. In this 190 study, a variant was considered a pathogenic damaging mutation if it was a protein-truncating mutation 191 caused by deleterious or frameshift mutation, or a missense mutation which has a confirmed association 192 with the disease, or a missense variant which has been classified as likely pathogenic according to the 193 ACMG standards and guidelines. All pathogenic mutations identified using Sanger sequencing were 194 confirmed by repeating the Sanger sequencing using an independent sample, while pathogenic 195 mutations identified using NGS were re-sequenced using Sanger sequencing. We selectively Sanger 196 sequenced only the pathogenic mutations identified using NGS via our own ABI 3500 Genetic Analyzer. 197 Notably, CRM had confirmed all variants other than neutral polymorphisms by Sanger sequencing. 198 Multiplex ligation-dependent probe amplification (MLPA) 199 200 Samples from Batch 1 were screened for large genomic rearrangements by MPLA using the SALSA MLPA 201 P002 BRCA1 and SALSA MLPA P090 BRCA2 probe mix following the manufacturers' protocol (MRC-202 Holland, Netherland). The MLPA analyses were performed by DNA Fragment Analysis on the ABI 3500

203 Genetic Analyzer. Data obtained were comparatively analysed using Coffalyser Net software

204 v.140721.1958 (MRC-Holland, Netherland).

205

206 Statistical analyses

207 Continuous data were presented as mean ± standard deviation (SD) or median and range where
 208 applicable. Mann-Whitney test was used to compare differences between the medians in two or more
 209 independent groups respectively. Chi-square or Fisher exact test was used to analyse the association

- 210 between two independent variables in the population. The statistical analysis was performed using SPSS
- version 17.0 software for Windows. A p value <0.05 was considered statistically significant.

212

213 **Results**

214 This was the first study of its kind in the Brunei breast cancer patients. Of the 120 recruited breast

cancer patients, 94 (78.3%) were Malays, 19 (15.8%) were Chinese, and 7 (5.8%) were others. The mean

age at diagnosis was 49.1±10.51 years, with peak of breast cancer incidence occurred in the 51-60 years

old age group, and one (0.8%) was a male breast cancer (Table 1).

218

Table 1. Demographic characteristics, personal and family history of cancer of study population

220 (*n*=120).

Characteristics	Mean (SD)	Frequency (%)
Age at diagnosis (year)	49.1 (10.51)	
Gender		
Male		1 (0.8)
Female		119 (99.2)
Ethnicity		
Malay		94 (78.3)
Chinese		19 (15.8)
Others		7 (5.8)
Age at first diagnosis (year)		
≤30		2 (1.7)
31-40		28 (23.3)

41-50		36 (30.0)
51-60		40 (33.3)
≥61		14 (11.7)
Cancer history		
Personal history of cancer		
Bilateral breast cancer		7 (5.8)
Ovarian cancer		2 (1.7)
Endometrium cancer		1 (0.8)
Liver cancer		1 (0.8)
Family history of cancer		
Breast and/or ovarian cancer in 1°	36 (30.0)	
Breast and/or ovarian cancer in 3°	9 (7.5)	
Other cancer in any degree of rela	28 (23.3)	
No family history of cancer at all		47 (39.2)
No of 1° relatives with breast cancer		
0		100 (83.3)
1		17 (14.2)
≥2		3 (2.5)
No of 2° relatives with breast cancer		
0		104 (86.7)
1		14 (11.7)
≥2	2 (1.7)	
No of 1° relatives with ovarian cancer		

0	115 (95.8)
≥1	5 (4.2)
No of 2° relatives with ovarian cancer	
0	118 (98.3)
≥1	2 (1.7)

221 1°, First-degree; 2°, Second-degree; 3°, Third-degree; 4°, Fourth-degree; SD, Standard Deviation

222

223 Seven (5.8%), two (1.7%), one (0.8%), and one (0.8%) patients had personal history of bilateral breast 224 cancers, ovarian cancer, endometrium cancer, and liver cancer, respectively. Assessment of family 225 history of breast and/or ovarian cancers was made based on whether the affected family members of 226 the patients were their first and/or second-degree relatives. Of the 120 cases, 36 (30.0%) had family 227 history of breast and/or ovarian cancers in their first and/or second-degree relatives while 47 (39.2%) 228 had no family history of cancers at all. Of patients with family history of breast cancer, 17 (14.2%) had 229 one first-degree family member affected with breast cancer, and 3 (2.5%) had two first-degree relatives 230 affected with breast cancer. For patients with family history of ovarian cancer, 5 (4.2%) and 2 (1.7%) had 231 only one affected member in the first- and second-degree relatives respectively (Table 1). 232

233 BRCA1 and BRCA2 mutations

Of the 95 variants identified in the study population, 29 (30.5%) and 66 (69.5%) were *BRCA1* and *BRCA2* variants respectively (S1 – S4 Tables). Of the 29*BRCA1* and 66*BRCA2* variants, 11 (37.9%) and 22 (33.3%) were novel respectively (S2– S4 Tables). No large rearrangements were detected in this study.

238	Prevalence of	pathogenic	mutations a	nd VUS
-----	---------------	------------	-------------	--------

239	Our study identified three frameshift BRCA2 deleterious mutations in 5 patients which led to the
240	introduction of premature stop codon in the resulting BRCA2 protein (S1 Table, Fig 1 and S2 Fig), and
241	one likely pathogenic BRCA2 missense mutation in one patient (S2 Table and Fig 1). Therefore, the
242	overall prevalence of germline BRCA1 and BRCA2 carriers among Brunei breast cancer patients were 0%
243	and 5%, respectively. All of the identified pathogenic and likely pathogenic mutations have been
244	reported, and were rare in the general population (<0.05% in gnomAD and 1000 Genome). One of the
245	BRCA2 deleterious mutations (c.5164_5165delAG) appeared to be a recurrent mutation.
246	
247	Fig 1. Schematic presentation of identified BRCA2 pathogenic mutations among Brunei breast cancer
248	cases.
249	
250	Excluding one patient with simultaneous germline pathogenic mutations, our study also identified
251	9BRCA1 and 32 BRCA2 VUS in 10and 31 patients, respectively (S3 Table). Thus, the prevalence of BRCA1
252	and BRCA2 VUS carriers among Brunei breast cancer patients were 8.3% and 25.8%, respectively. Four of
253	the BRCA1 VUS and 14 of the BRCA2 VUS were novel while the others have been reported. Almost all of
254	the reported VUS have no recorded data in the general population (S3 Table) while those that with data
255	were found to be rare in the general population (<0.05% in gnomAD and 1000 Genome).
256	
257	Characteristics of Brunei's germline pathogenic BRCA carriers
258	S5 Table shows the characteristics of the Brunei breast cancer patients with deleterious and damaging
259	missense mutations. Collectively, one (16.7%) of the carriers was male while the rest were female. Two
260	(33.3%) of the affected were diagnosed with bilateral breast cancer. The molecular subtype of the first
261	breast cancer diagnosis showed that one (16.7%) patient was TNBC, one (16.7%) was Luminal A, while

262	the rest were Luminal B. Two (33.3%) of the carriers had an age at onset of ≤40 years while the others
263	were ≥40 years, and one (16.7%) of the carriers had no family history of cancers at all. The proportion of
264	our BRCA1/2 carriers by ethnicity was 3/19 (15.8%) and 3/94 (3.2%) in Chinese and Malay, respectively.
265	There is no significant difference observed between the overall median age of diagnosis among
266	carriers (48 years) and non-carriers (49 years) (p =0.609, Table 2). Brunei BRCA2 carriers were found to
267	be more likely to have family history of breast and/or ovarian cancer, and have≥1 affected family
268	members in the first-degree with breast cancer ($p = 0.027$ and $p = 0.001$ respectively, Table 2). There are
269	no significant association between Brunei BRCA2 carriers and other selected clinical characteristics in
270	Table 2.

271

Table 2. Association analysis of Brunei breast cancer patients with pathogenic mutation with selected
 clinical characteristics.

	Total (n =		BRCA2 carriers		Non-BRCA2		<i>p</i> -value ^{a b}
	12	20)	(<i>n</i> = 6)		carriers (<i>n</i> = 114)		
	n	%	n	%	n	%	
Age at diagnosis (years)			Median	(range)	Median	(range)	
			48 (31	L — 59)	49 (27	7 – 71)	0.609
Age range (years)							
≤ 40	30	25.0	2	33.3	28	24.6	0.741
41 – 50	36	30.0	1	16.7	35	30.7	
51 – 60	40	33.3	3	50.0	37	32.5	
> 60	14	11.7	0	0	14	12.3	
Ethnicity							
Malay	94	78.3	3	50.0	91	79.8	0.089

Chinese	19	15.8	3	50.0	16	14.0	
Others	7	5.8	0	0	7	6.1	
Bilateral breast cancer							
Yes	8	6.7	2	33.3	6	5.3	0.051
No	112	93.3	4	66.7	108	94.7	
Estrogen Receptor (ER)							
Positive	72	60.0	4	66.7	68	59.6	1
Negative	48	40.0	2	33.3	46	40.4	
Progesterone Receptor (PR)							
Positive	62	51.7	4	66.7	58	50.9	0.681
Negative	58	48.3	2	33.3	56	49.1	
Her2							
Positive	73	60.8	3	50.0	70	61.4	0.678
Negative	47	39.2	3	50.0	44	38.6	
Triple negative breast cancer							
(TNBC)	15	12.5	1	16.7	14	12.3	0.559
Yes	105	87.5	5	83.3	100	87.7	
No							
Family history of cancer ^c							
Yes	72	60.0	5	83.3	67	58.8	0.400
No	48	40.0	1	16.7	47	41.2	
Family history of breast and/or							
ovarian cancer							

Yes	45	37.5	5	83.3	40	35.1	0.027
No	75	62.5	1	16.7	74	64.9	
Number of affected first-							
degree relatives with breast							
cancer	100	83.3	2	33.3	98	86.0	0.001
0	17	14.2	2	33.3	15	13.2	
1	3	2.5	2	33.3	1	0.9	
≥2							
Number of affected second-							
degree relatives with breast							
cancer	104	86.7	5	83.3	99	86.8	0.585
0	14	11.7	1	16.7	13	11.4	
1	2	1.7	0	0	2	1.8	
≥ 2							
Number of affected first-							
degree relatives with ovarian							
cancer	115	95.8	5	83.3	110	96.5	0.230
0	5	4.2	1	16.7	4	3.5	
≥1							
Number of affected second-							
degree relatives with ovarian							
cancer	118	98.3	5	83.3	113	99.1	0.098
0	2	1.7	1	16.7	1	0.9	
≥1							

Vital status							
Alive	95	79.2	4	66.7	91	79.8	0.603
Deceased	25	20.8	2	33.3	23	20.2	

^a Mann-Whitney test or Fisher's Exact test whichever appropriate

^bStatistically significant *p*-values are indicated in bold

- ^c inclusive of breast, ovarian and other cancers
- 277

278 **Discussion**

279 Prior to introducing cancer genetic test in a community, genetic variation profile of the said community 280 must first be known to have an overview of the contribution of genetics in the population. Although 281 cancer incidence and mortality in Brunei Darussalam have been increasing for the past 10 years, there 282 are still no data available on the proportion of Brunei cancer patients carrying germline or somatic 283 mutations in their cancer predisposing gene. BRCA1 and BRCA2 gene frequencies in breast and ovarian 284 cancer patients in other East-Asian populations have been continuously researched on which had led to 285 the discovery of potential founder mutations [29,39,55,65]. Notably, identifying who should be offered 286 cancer genetic test in the Asian community remains challenging as the currently available guidelines for testing have been shown to omit at least 20% of patients carrying BRCA mutations from being tested 287 288 [21], suggesting the testing criteria on *BRCA1* and *BRCA2* germline mutations which have been well 289 established in the Caucasian population were not readily applicable to the Asian population. 290 Our study, which is the first genetic study of its kind in Brunei, showed that the overall 291 combined frequency of germline pathogenic BRCA1 and BRCA2 mutation carriers among 120 recruited 292 Brunei's breast cancer patients was 5% (n = 6), which is lower than those reported at 12.3% in women of 293 European descendent [66]. Our data are relatively similar to previously reported prevalence from other

294	Asian countries in particular from the South-East Asian region which is 4.7% in Malaysia [21] and 5.1% in
295	the Philippines [39] except for Singapore [19] and Vietnam [40] which were reported at 17.4% and 0.8%,
296	respectively. Interestingly, other Asian countries outside of the South-East Asian region had reported a
297	relatively higher prevalence of BRCA1 and BRCA2 mutations which was almost similar (or higher for
298	some) to the findings reported in European women with14.0% in Korea [67] and 24.7% in Pakistan [68].
299	Japan [69], Hong Kong [54,55] and China [20] however, reported a prevalence of 4.2%, 7.9% to 8.8%,
300	and 8.3%, respectively. Comparatively, all these countries had reported prevalence of germline
301	mutations in both BRCA1 and BRCA2 genes while all germline BRCA mutations identified in our study
302	were attributed to BRCA2 gene only. Our findings were consistent with those from all the
303	aforementioned Asian countries where most of the germline pathogenic BRCA mutations in the Brunei
304	breast cancer patients were identified in the BRCA2 gene compared to BRCA1 which was reported to be
305	more affected in the European women [66].
306	Our study showed that one recurrent deleterious frameshift mutation, BRCA2c.5164_5165delAG
307	(S1722Yfs*1725), was identified in 3 (2.5%) patients of Chinese ethnicity. In particular two of the
308	affected patients, 4G-004 and 4G-003, were related to each other (mother and daughter, respectively).
309	This mutation was suggested to have a founder effect in the Southern China province population. While
310	it was unknown whether our Chinese index cases ancestry were originally from the Southern China,
311	there was still a probability that the occurrence of this mutation might be linked to a common ancestral
312	origin. Moreover, this mutation has also been reported in the Chinese ethnicity in Malaysia [34] and
313	Singapore [18] which further support the probability of the founder mutation theory. However, it is
314	acknowledged that the probability could be slightly lowered due to the fact that two out of three of the
315	carriers of this mutation were relatives where the variant could have been inherited from their maternal
316	side. Although the other two deleterious frameshift BRCA2 mutations identified in this study only occur
317	in one (0.8%) of the study population, the mutations c.3170_3174delAGAAA (K1057Tfs*1064) and

318 c.1763 1766delATAAA (N588Sfs*612) had each been reported as a founder mutation in the French-319 Canadian [52] and Colombian [51] populations respectively. The probability of these two mutations being linked to the two populations was highly unlikely as the carriers were both of Malay ethnicity, and the 320 321 family history from both carriers did not support a common ancestral origin with the aforementioned 322 populations. Interestingly, in the South-East Asia (SEA) population, the BRCA2 mutation 323 c.1763 1766delATAA (N588Sfs*612) was only ever reported in a breast cancer patient in Sarawak, 324 Malaysia who was diagnosed <40 years old with triple negative breast cancer and family history of 325 breast cancer [33]. This observation suggests that all populations have different population genetic 326 predisposition towards breast cancer. Pathogenic mutations determined as a founder effect in one 327 population may only be detected in a small frequency in other populations of different ancestral origin. 328 Moreover, for the two patients identified with these mutations, there is a 50% chance that their family 329 members carried the same BRCA2 mutation that could result in the development of breast cancer in 330 these family members.

331 The three aforementioned frameshift mutations introduced premature stop codon which was 332 known to be associated with an increased risk of breast cancer. The effect of frameshift mutations 333 resulting in the stop codon has been shown to destabilise BRCA mRNA leading to a haplo-insufficiency 334 resulting in allelic imbalance [70]. This in turn caused a significant reduction in the expression ratio 335 between the mutant and the wild-type alleles [70]. The allelic imbalance resulted in a decreased level of 336 both BRCA transcripts and proteins contributing to the increased risk of breast cancer [70]. The resulting 337 BRCA2 truncated protein from the three identified pathogenic variants in our study showed a loss of 338 important domains, including: (1) the BRC repeats domain (all for c.1763_1766delATAAA, BRC-2 to BRC-339 8 for c.3170_3174delAGAAA, BRC-6 to BRC-8 for c.5164_5165delAG); (2) the DNA binding domain 340 (DBD); and (3) the two nuclear localisation signals (NLS) in the C-terminus region (S2 Fig). The highly 341 conserved eight BRC repeat domains and the DNA binding domains in the BRCA2 protein mediate the

interaction of ssDNA and/or dsDNA with RAD51 molecules in the homologous recombination (HR) 342 343 regulated DNA repair pathway. In HR regulated pathway, BRCA2 is localised onto sites of dsDNA break by forming complex with other proteins including BRCA1 and PALB2, before it mediates the loading of 344 345 RAD51 onto the ssDNA and initiate the repair. Loss of these RAD51-interacting domains in the BRCA2 346 protein prevent DNA repair in error-free HR regulated pathway, allowing the error-prone non-347 homologous end joining (NHEJ) pathway to take over. Moreover, it has been demonstrated that the 348 deletions of all RAD51-interacting domains cause embryonic lethality in mice, but deletion of several 349 BRC repeats motif showed a less severe phenotype although it was observed that the mice died very 350 young from cancer development [71]. The DBD in BRCA2 was also involved in transcriptional activity 351 where it bound ssDNA before drawing histone modifiers which led to the initiation of the transcriptional 352 process [10]. The loss of the two NLS in the C-terminus region due to the truncation was reported to 353 result in the mutant BRCA2 being cytoplasmic since it could not be translocated into the nucleus, hence 354 causing it to become non-functional [72]. 355 One likely pathogenic missense mutation was identified in the only patient who have no family 356 history of cancers at all (S5 Table). BRCA2 mutation c.8524C>T (R2842C) was located in the BRCA2 DNA 357 binding domain suggesting it can affect the protein function. An assessment made on the clinical relevance of VUS identified in the BRCA2 DBD by using a validated functional assay of BRCA2 358 359 homologous recombination (HR) DNA-repair activity had showed the mutation R2842C had 360 intermediate or partial effects on BRCA2 function [57]. Another functional assessment of human BRCA2 variants using a mouse embryonic stem cell (mESC)-based assay supported that although the mutation 361 362 R2842C is able to complement the loss of cell viability, its capacity to perform BRCA2 function i.e., 363 homology directed repair (HDR) showed more than 50% reduction in HDR capacity compared with wild-364 type BRCA2 expressing cells[58,59]. These results suggested that the mutation R2842C is characterized 365 as a hypomorphic variant in which the studies concluded that the mutation is intermediate between

pathogenic and likely pathogenic variants [58,59]. In our study, the effect of thehypomorphic*BRCA2*germline mutation R2842C was observed in patient 2G-022, in which the patient had an increased
susceptibility to familial breast and/or ovarian cancers even though she did not have any family history
of cancers at all. Notably, none of the founder mutations found in the SEA population were identified in
our study population.

371 Similar to other genetic variation analysis conducted in other populations, 41 (43.2%) of the 372 identified variants in the study population were classified as VUS (S3 Table). The overall combined 373 frequency of patients with BRCA1 and BRCA2 VUS in the study was 35 (29.2%), in which 6 patients have 374 both BRCA1 and BRCA2 VUS. Our findings are higher than those reported in other populations, such as 375 5.7% in European [66], and 1.6% in Malaysian [21] women, respectively. It has been shown that the 376 prevalence of VUS in a study population was inversely correlated with the total number of individuals 377 tested [66]. Hence, if our total study cohort population was higher than 120, our prevalence could be 378 relatively similar with other countries' findings as demonstrated in three other Asian countries' studies 379 conducted comprising over 2500 breast cancer patients; namely China [20], Malaysia [21], and Japan 380 [69].

Collectively, Brunei *BRCA2* carriers exhibited almost the same phenotypic association pattern as other *BRCA2* carriers in China [20] and Malaysia [21], where Brunei *BRCA2* carriers were found to be more likely to have family history of breast and/or ovarian cancers, and having more first-degree relatives affected with breast cancer. Consistent with other studies, our findings showed that TNBC is not significantly associated with *BRCA2* carriers[17,19,21].

386 It is acknowledged that this study is limited by the small size of the study population even 387 though it was the first and largest cohort study for genetic testing in Brunei. Future study on a larger 388 cohort of study population could confirm our findings on the prevalence of germline mutations in the 389 Brunei breast cancer population. Moreover, it could also provide a more comprehensive data for

390	phenotypic characteristics of predisposing carriers in our breast cancer population attributed to each
391	gene. Our current study showed that none of our study population tested for BRCA1 and BRCA2 large
392	rearrangements showed positive for the test. Therefore, there are no data on the contribution of large
393	rearrangement of BRCA1 and BRCA2 in the Brunei breast cancer population presented in this thesis.
394	Given the constraint in getting resources for performing large rearrangements analysis in some of the
395	study population (Batch 2), there is an approximately 10% probability that some carriers may have been
396	missed in this study [19].

397

398 **Conclusions**

399 The findings from this study have highlighted the contribution of genetics, specifically BRCA1 and BRCA2 400 genes in 120 unselected series of Brunei breast cancer population. The prevalence of germline BRCA1 401 and BRCA2 mutation carriers among Brunei breast cancer patients (5%) is similar to that of other Asian 402 populations confirming the difference in contribution of BRCA1 and BRCA2 in both the Caucasian and 403 Asian populations. One BRCA2 mutation observed only in Brunei breast cancer population of Chinese 404 ethnicity contributes to the probability of the mutation being a founder effect in the Southern Chinese population. Future studies should investigate the contribution of germline mutations of BRCA1 and 405 406 BRCA2 genes in a larger case-control cohort study of Brunei breast cancer population to confirm our 407 findings.

408

409 Acknowledgements

We sincerely acknowledge all the doctors, nurses and staff from TBCC for their cooperation and also to
CRM and First Base Laboratories Sdn Bhd for their contribution to the study. We would like to thank our
undergraduate students; Jacinda Lim Xin Yan and Hon Kar Yee; who have taken a small project under

- this study. Finally, we would like to express our gratitude to all patients who have participated in our
- 414 research study. MRWHAH received a grant from Universiti Brunei Darussalam to fund the initial part of
- 415 this study [UBD/PNC2/2/RG/1(186))]
- 416

417 **References**

- 418 1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Piñeros M, et al. Estimating the global
- 419 cancer incidence and mortality in 2018: GLOBOCAN sources and methods.Int J Cancer.
- 420 2019;144:1941-53. doi: https://doi.org/10.1002/ijc.31937
- 421 2. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and
- 422 progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular
- 423 pathogenesis. Genes Dis. 2018;5:77-106. doi: https://doi.org/10.1016/j.gendis.2018.05.001
- 424 3. Miki Y, Swensen J, Shattuck-Eidens D, Futreal P, Harshman K, Tavtigian S, et al. A strong candidate
- for the breast and ovarian cancer susceptibility gene *BRCA1*. Science. 1994;266(5182):66-71.
- 426 4. Wooster R, Neuhausen S, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer
- 427 susceptibility gene, *BRCA2*, to chromosome 13q12-13. Science. 1994;265:2088-90.
- 428 5. Xu B, Kim S, Kastan M. Involvement of *Brca1* in S-Phase and G2-Phase checkpoints after ionizing
- 429 irradiation. Mol Cell Biol. 2001;21(10):3445-50.
- 430 6. Starita L, Parvin J. The multiple nuclear functions of *BRCA1*: transcription, ubiquitination and DNA
- 431 repair. CurrOpin Cell Biol. 2003;15:345-50.
- 432 7. Davies O, Pellegrini L. Interaction with the *BRCA2* C-terminus protects RAD51-DNA filaments from
- disassembly by BRC repeats. Nat Struct Mol Biol. 2007;14:475-83. doi:10.1083/nsmb1251.

- 434 8. Tassone P, Di Martino M, Ventura M, Pietragalla A, Cucinotto I, Calimeri T, et al. Loss of BRCA1
- function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo.
- 436 Cancer Biol Ther. 2009;8(7):648-53.
- 437 9. Clark S, Rodriguez A, Snyder R, Hankins G, Boehning D. Structure-Function of the tumor suppressor
- 438 BRCA1. Comput Struct Biotec. 2012;1(1):e201204005.
- 439 10. Orr KS, Savage KI. The BRCA1 and BRCA2 Breast and Ovarian Cancer Susceptibility Genes –
- 440 Implications for DNA Damage Response, DNA Repair and Cancer Therapy. In: Chen C, editors.
- 441 Advances in DNA Repair. London: IntechOpen; 2015. p. 217-53.
- 442 11. Xu B, O'Donnell AH, Kim ST, Kastan MB. Phosphorylation of Serine 1387 in Brca1 is specifically
- required for the Atm-mediated S-Phase checkpoint after ionizing irradiation. Cancer Res.
- 444 2002;62:4588-91.
- 12. Fabbro M, Savage K, Hobson K, Deans AJ, Powell SN, McArthur GA, et al. BRCA1-BARD1 complexes
- 446 are required for *p53*^{Ser-15} phosphorylation and a G1/S arrest following ionizing radiation-induced
- 447 DNA damage. J Biol Chem. 2004;279(30):31251-8.
- 13. Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer
- 449 evolution. Nucleic Acids Res. 2006;34(5):1416-26.
- 450 14. Park MA, Seok YJ, Jeong G, Lee JS. SUMO1 negatively regulates BRCA1-mediated transcription, via
- 451 modulation of promoter occupancy. Nucleic Acids Res. 2008;36(1):263-83. doi:10.1093/nar/gkm969.
- 452 15. Roy R, Chun J, Powell SN. *BRCA1* and *BRCA2*: different roles in a common pathway of genome
- 453 protection. Nat Rev Cancer. 2016;12(1):68-78.
- 454 16. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, the BRCA1 and
- 455 BRCA2 Cohort Consortium. Risks of breast, ovarian and contralateral breast cancer for BRCA1 and
- 456 *BRCA2* mutation carriers. JAMA. 2017;317(23):2402-16. doi:10.1001/jama.2017.7112.

- 457 17. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of
- 458 breast and ovarian cancers among *BRCA1* and *BRCA2* mutation carriers: results from the Consortium
- 459 of Investigators of Modifiers of *BRCA1/2* (CIMBA). Cancer EpidemBiomar. 2012;21(1):134-47.
- 460 doi:10.1158/1055-9965.EPI-11-0775.
- 461 18. Wong ESY, Shekar S, Chan CHT, Hong LZ, Poon SY, Silla T, et al. Predictive Factors for *BRCA1* and
- 462 *BRCA2* Genetic Testing in an Asian Clinic-Based Population. PLoS ONE. 2015;10(7):e0134408.
- 463 19. Wong ESY, Shekar S, Met-Domestici M, Chan C, Sze M, Yap YS, et al. Inherited breast cancer
- 464 predisposition in Asians: multigene panel testing outcomes from Singapore. Genom Med.
- 465 2016;1:15003. doi:10.1038/npjgenmed.2015.3.
- 466 20. Lang GT, Shi JX, Hu X, Zhang CH, Shan L, Song CG, et al. The spectrum of *BRCA*-associated breast
- 467 cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing. Int J
- 468 Cancer. 2017;141:129-42.
- 469 21. Wen WX, Allen J, Lai KN, Mariapun S, Hasan SN, Ng PS, et al. Inherited mutations in BRCA1 and
- 470 BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls
- 471 from Malaysia. J Med Genet. 2018;55:97-103. doi:10.1136/jmedgenet-2017-104947.
- 472 22. Wallace AJ. New challenges for BRCA testing: a view from the diagnostic laboratory. Eur J Hum
- 473 Genet. 2016;24:S10-8. doi:10.1038/ejhg.2016.94.
- 474 23. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast
- 475 cancer in patients with a germline *BRCA* mutation. New Engl J Med. 2017;377:523-33.
- 476 doi:10.1056/NEJMoa1706450.
- 477 24. Dougherty BA, Lai Z, Hodgson DR, Orr MCM, Hawryluk M, Sun J, et al. Biological and clinical evidence
- 478 for somatic mutations in BRCA1 and BRCA2 as predictive markers for Olaparib response in high-
- grade serous ovarian cancers in the maintenance setting. Oncotarget. 2017;8(27):43653-61.

480	25.	Department of	Economic P	lanning and	l Develop	ment (DEPD). Brunei Darussalam	key indicators
-----	-----	---------------	------------	-------------	-----------	------------	----------------------	----------------

- 481 (BDKI) [Internet]. Brunei Darussalam: DEPD; 2018 [accessed 2019 Mar 21]. Available from:
- 482 http://www.depd.gov.bn/DEPD%20Documents%20Library/DOS/BDKI/BDKI_2018.pdf
- 483 26. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018:
- 484 GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca-
- 485 Cancer J Clin. 2018;68:394-424.
- 486 27. Chong VH, Telisinghe PU. Rising incidence of breast cancer in Brunei Darussalam. Brunei Int Med J.
- 487 2011;7(5):260-8.
- 488 28. Tan S, Abdullah MS, Telisinghe PU, Ramasamy R. Breast cancer in Brunei Darussalam Incidence and
- the role of evaluation of molecular markers. Brunei Int Med J. 2011;7(5):250-9.
- 490 29. SngJH, Ali AB, Lee SC, Zahar D, Wong JEL, Blake V, et al. *BRCA1* c.2845insA is a recurring mutation
- 491 with a founder effect in Singapore Malay women with early onset breast/ovarian cancer. J Med492 Genet. 2003;40:e117.
- 493 30. Ho GH, Phang BH, Ng ISL, Law HY, Soo KC, Ng EH. Novel Germline *BRCA1* Mutations Detected in
- 494 Women in Singapore who Developed Breast Carcinoma before the Age of 36 Years. Cancer.
- 495 2000;89:811-6.
- 496 31. Lim YL, Iau PTC, Ali AB, Lee SC, Wong JEL, Putti TC, et al. Identification of novel *BRCA* large genomic

497 rearrangements in Singapore Asian breast and ovarian patients with cancer. Clin Genet.

498 2007;71:331-342.

- 499 32. Thirthagiri E, Lee SY, Kang P, Lee DS, Toh GT, Selamat S, et al. Evaluation of BRCA1 and BRCA2
- 500 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low
- 501 incidence of breast cancer. Breast Cancer Res.2008;10:R59. doi:10.1186/bcr2118.

- 502 33. Yang XR, Devi BCR, Sung H, Guida J, Mucaki EJ, Xiao Y, et al. Prevalence and spectrum of germline
- 503 rare variants in *BRCA1/2* and *PALB2* among breast cancer cases in Sarawak, Malaysia. Breast Cancer
- 504 Res Treat. 2017;165(3):687-97. doi:10.1007/s10549-017-4356-8.
- 505 34. Ng PS, Wen WX, Fadlullah MZH, Yoon SY, Lee SY, Thong MK, et al. Identification of germline
- alterations in breast cancer predisposition genes among Malaysian breast cancer patients using
- 507 panel testing. Clin Genet. 2016. doi: 10.1111/cge.12735.
- 35. Balraj P, Khoo ASB, Volpi L, Tan JAMA, Nair S, Abdullah H. Mutation Analysis of the *BRCA1* Gene in
 Malaysian Breast Cancer Patients. Singapore Med J. 2002;43(4):194-7.
- 510 36. Toh GT, Kang P, Lee SSW, Lee DSC, Lee SY.BRCA1 and BRCA2 Germline Mutations in Malaysian
- 511 Women with Early-Onset Breast Cancer without a Family History. PLoS ONE. 2008;3(4):e2024.
- 512 doi:10.1371/journal.pone.0002024.
- 513 37. Kang P, Mariapun S, Phuah SY, Lim LS, Liu J, Yoon SY, et al. Large *BRCA1* and *BRCA2* genomic
- 514 rearrangements in Malaysian high-risk breast-ovarian cancer families. Breast Cancer Res

515 Treat.2010;124:579-84.

516 38. Tria IV F, Ang D, Andal JJ, Que FV, Cabral LK, Dimalibot R, et al. Prevalence of Germline *Brca1* and

517 *Brca2* Mutation Among Filipinos. Cancer Res J. 2019;7(3):79-86. doi: 10.11648/j.crj.20190703.12

- 518 39. Matsuda MLDL, Liede A, Kwan E, Mapua CA, Cutiongco EMC, Tan A, et al. BRCA1 and BRCA2
- 519 mutations among breast cancer patients from the Philippines. Int. J. Cancer. 2002;98:596-603.
- 40. Ginsburg OM, Dinh NV, To TV, Quang LH, Linh ND, Duong BTH, et al. Family history, *BRCA* mutations
- and breast cancer in Vietnamese women. Clin Genet. 2010.doi: 10.1111/j.1399-0004.2010.01545.x.
- 41. Thuan TV, Chu NV, Khoa PH, Quang NT, Tu DV, Tho NTQ, et al. A Novel *BRCA1* Gene Mutation
- 523 Detected with Breast Cancer in a Vietnamese Family by Targeted Next-Generation Sequencing: A
- 524 Case Report. Breast Cancer Basic Clin Res.2020;14:1-4. doi: 10.1177/1178223420901555

- 42. Patmasiriwat P, Bhothisuwan K, Sinilnikova OM, Chopin S, MethakijvaroonS, Badzioch M, et al.
- 526 Analysis of Breast Cancer Susceptibility Genes BRCA1 and BRCA2 in Thai Familial and Isolated Early-
- 527 Onset Breast and Ovarian Cancer. Hum Mutat. 2002;520. doi: 10.1002/humu.9049
- 43. Jadsri S, Chareonsirisuthigul T, Rerkamnuaychoke B, Dejsuphong D, Tunteeratum A,
- 529 Mahasirimongkol S. BRCA1 and BRCA2 Large Genomic Rearrangements Screening in Thai Familial
- 530 Breast Cancer Patients by Multiplex Ligation-dependent Probe Amplification (MLPA). Naresuan
- 531 University Journal: Science and Technology. 2016;24(2).
- 44. Purnomosari D, Paramita DK, Aryandono T, Pals G, van Diest PJ. A novel BRCA2 mutation in an
- 533 Indonesian family found with a new, rapid, and sensitive mutation detection method based on
- pooled denaturing gradient gel electrophoresis and targeted sequencing. J Clin Path. 2005;58:493-9.
- 535 doi:10.1136/jcp.2004.020388
- 45. Purnomosari D, Pals G, Wahyono A, Aryandono T, Manuaba TW, Haryono SJ, et al. BRCA1 and BRCA2
- 537 germline mutation analysis in the Indonesian population. Breast Cancer Res Treat. 2007;106:297-
- 538 304.
- 46. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, et al. Confirmation of *BRCA1* by
- 540 analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat
- 541 Genet.1994;8:399–404.
- 47. Wagner T, Stoppa-Lyonnet D, FleischmannE, Muhr D, Pages S, Sandberg T, et al. Denaturing high-
- 543 performance liquid chromatography detects reliably *BRCA1* and *BRCA2* mutations.
- 544 Genomics.1999;62(3):369-76.
- 48. MaloneKE, Daling JR, DoodyDR, Hsu L, Bernstein L, Coates RJ, et al. Prevalence and predictors of
- 546 BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black
- 547 American women ages 35 to 64 years. Cancer Res.2006;66(16):8297–308.

- 548 49. Afgan E, Baker D, Batut B, van den Beek M, Bouvier D,Čech M, et al. The Galaxy platform for
- 549 accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids
- 550 Res.2018;46(W1):W537-44. doi:10.1093/nar/gky379.
- 551 50. RichardsS, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the
- 552 interpretation of sequence variants: a joint consensus recommendation of the American College of
- 553 Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med.
- 554 2015;17:405-23. doi:https://doi.org/10.1038/gim.2015.30
- 555 51. Torres D, Bermejo JL, Rashid MU, Briceño I, Gil F, Beltran A, et al. Prevalence and Penetrance of
- 556 BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients. Nat Sci
- 557 Rep.2017;7:4713. doi:10.1038/s41598-017-05056-y.
- 558 52. Janavičius R. Founder *BRCA1/2* mutations in the Europe: implications for hereditary breast-ovarian
 559 cancer prevention and control. EPMA Journal, 2010;1:397-412.
- 560 53. Sun J, Meng H, Yao L, Meng L, Bai J, Zhang J, et al. Germline mutations in cancer susceptibility genes
- in a large series of unselected breast cancer patients. Clin Cancer Res. 2017;23(20):6113-9. doi:
- 562 10.1158/1078-0432.CCR-16-3227.
- 563 54. Kwong A, Shin VY, Au CH, Law FBF, Ho DN, Ip BK, et al. Detection of Germline Mutation in Hereditary
- 564 Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel. J Mol Diagn.
- 565 2016;18:580-94. doi: http://dx.doi.org/10.106/j.jmoldx.2016.03.005.
- 566 55. Kwong A, Ho JCW, Shin VY, Kurian AW, Tai E, Esserman LJ, et al. Rapid detection of BRCA1/2
- 567 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot
- 568 genotyping panel. Oncotarget. 2018;9(8):7832-43.
- 569 56. Guidugli L, Pankratz VS, Singh N, Thompson J, Erding CA, Engel C, et al. A classification model for
- 570 BRCA2 DNA binding domain missense variants based on homology directed repair activity. Cancer
- 571 Res. 2013;73(1):265-75. doi:10.1158/0008-5472.CAN-12-2081.

- 57. Guidugli L, Shimelis H, Masica DL, Pankratz VS, Lipton GB, Singh N, et al. Assessment of the clinical
- 573 relevance of *BRCA2* missense variants by functional and computational approaches. Am J Hum
- 574 Genet. 2018; 102: 233-48.
- 575 58. Mesman RLS, Calléja FMGR, Hendriks G, Morolli B, Misovic B, Devilee P, et al. The functional impact
- 576 of variants of uncertain significance in *BRCA2*. Genet Med. 2019; 21: 293-302. doi:
- 577 https://doi.org/10.1038/s41436-018-0052-2
- 578 59. Caburet S, Heddar A, Dardillac E, Creux H, Lambert M, Messiaen S, et al. Homozygous
- 579 hypomorphicBRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anaemia trait.
- 580 J Med Genet. 2020; 0: 1-10. doi:10.1136/jmedgenet-2019-106672.
- 581 60. Bouwman P, van der Gulden H, van der Heiden I, Drost R, Klijn CN, Prasetyanti P, et al. A high-
- 582 throughput functional complementation assay for classification of *BRCA1* missense variants. Cancer
- 583 Discov. 2013; 3(10): 1142-55. doi:10.1158/2159-8290.CD-13-0094.
- 584 61. Xu GP, Zhao Q, Wang D, Xie WY, Zhang LJ, Zhou H, et al. The association between BRCA1 gene
- polymorphism and cancer risk: a meta-analysis. Oncotarget. 2018; 9(9): 8681-94.
- 586 62. Park JS, Nam EJ, Park HS, Han JW, Lee JY, Kim J, et al. Identification of a novel *BRCA1* pathogenic
- 587 mutation in Korean patients following reclassification of *BRCA1* and *BRCA2* variants according to the
- 588 ACMG Standards and Guidelines using relevant ethnic controls. Cancer Res Treat. 2017; 49(4): 1012-
- 589 21. doi: https://doi.org/10.4143/crt.2016.433

590 63. Findlay GM, Daza RM, Martin B, Zhang MD, Leith AP, Gasperini M, et al. Accurate classification of

- 591 *BRCA1* variants with saturation genome editing. Nature. 2018; 562(7726): 217-22.
- 592 doi:10.1038/s41586-018-0461-z.
- 593 64. Sigurdson AJ, Hauptmann M, Chatterjee N, Alexander BH, Doody MM, Rutter JL, et al. Kin-cohort
- 594 estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1
- interacting and growth factor genes. BMC Cancer. 2004; 4(9).

- 596 65. Karami F, MehdipourP. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in
- 597 Breast Cancer. Biomed Res Int. 2013: 1-21.
- 598 66. Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, et al. BRCA1 and BRCA2 mutations
- in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.
- 600 Cancer.2009; 115(10): 2222-33. doi: 10.1002/cncr.24200.
- 601 67. Kim HN, Shin MH, Lee R, Park MH, Kweon SS. Novel Germline Mutations of BRCA1 and BRCA2 in
- 602 Korean Familial Breast Cancer Patients. Chonnam Med J. 2019; 55: 99-103.
- 603 https://doi.org/10.4068/cmj.2019.55.2.99.
- 604 68. Rashid MU, Muhammad N, Naeemi H, Khan FA, Hassan M, Faisal S, et al. Spectrum and prevalence
- of *BRCA1/2* germline mutations in Pakistani breast cancer patients: results from a large
- 606 comprehensive study. Hered Cancer in Clin Pr. 2019; 17(27). doi: https://doi.org/10.1186/s13053-
- 607 019-0125-5.
- 608 69. Momozawa Y, Iwasaki Y, Parsons MT, Kamatani Y, Takahashi A, Tamura C, et al. Germline pathogenic
- variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nature Comm.
- 610 2018; 9: 4083. doi: 10.1038/s41467-018-06581-8.
- 611 70. Chen X, Truong TT, Weaver J, Bove BA, Cattie K, Armstrong BA, et al. Intronic alterations in BRCA1
- and *BRCA2*: effect on mRNA splicing fidelity and expression. Hum Mutat. 2006; 27(5): 427-435.
- 613 71. Donoho G, Brenneman MA, Cui TX, Donoviel D, Vogel H, Goodwin EH, et al. Deletion of *Brca2* exon
- 614 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.
- 615 Gene ChromosomeCanc.2003; 36: 317-31. doi: https://doi.org/10.1002/gcc.10148.
- 616 72. Spain BH, Larson CJ, Shihabuddin LS, Gage FH, Verma IM. Truncated BRCA2 is cytoplasmic:
- 617 Implications for cancer-linked mutations. PNAS. 1999; 96(24): 13920-5.
- 618
- 619

620 Supporting information

- 621 S1 Fig. The study strategy to detect *BRCA1* and *BRCA2* mutations.
- 622 S2 Fig. Schematic presentation of truncated BRCA2 protein in the study population. The three
- 623 identified BRCA2 pathogenic mutations, c.1763_1766delATAAA, c.3170_3174delAGAAA and
- 624 c.5164_5165delAG led to BRCA2 protein truncation at amino acids positions 612, 1064, and 1725
- respectively. The truncation caused the loss of important domains affecting the function of BRCA2
- 626 predominantly in the HR-regulated DNA repair pathway.
- 627 S1 Table. Deleterious mutations identified in the Brunei breast cancer patients.*, Termination; AA,
- amino acid; AF, Allele Frequency; Freq, Frequency; FS, Frameshift; Nov, Novel; Ref, Reference; Rep,
- 629 Reported.
- 630 **S2 Table. Damaging missense variants identified in the Brunei breast cancer patients.** AA, amino acid;
- AF, Allele Frequency; B, Benign; D, Damaging; Freq, Frequency; N, Neutral; NA, Not Available; Nov,
- Novel; PrD, Probably Damaging; Ref, Reference; Rep, Reported; T, Tolerated.
- 633 S3 Table. Missense variants identified in the Brunei breast cancer patients. AA, amino acid; AF, Allele
- 634 Frequency; B, Benign; D, Damaging; Freq, Frequency; N, Neutral; NA, Not Available; Nov, Novel; PoD,
- 635 Possibly Damaging; PrD, Probably Damaging; Ref, Reference; Rep, Reported; T, Tolerated; VUS, Variant
- 636 of uncertain significance.
- 637 S4 Table. Synonymous variants identified in the Brunei breast cancer patients. AA, amino acid; AF,
- Allele Frequency; Freq, Frequency; NA, Not Available; Nov, Novel; Rep, Reported.
- 639 S5 Table. Characteristics of the Brunei breast cancer patients with deleterious and damaging missense
- 640 mutations.+, Positive; -, Negative; 'XX, year diagnosed or deceased; AA, Amino acid; Aff, Affected; Au,
- Aunt; Bil., Bilateral; Br, Breast; Bro, Brother; Ca, Cancer; Chi, Chinese; Cou, Cousin; Dau, Daughter; de.,
- deceased; dx., diagnosed; DC, Ductal carcinoma; DCIS, Ductal carcinoma in situ; ER, Oestrogen receptor;

- 643 Eth, Ethnicity; F, Female; Fa, Father; Gen, Gender; GrMo, Grandmother; Her2, Human Epidermal Growth
- 644 Receptor-2; IDC, Invasive ductal carcinoma; ILC, Invasive lobular carcinoma; L, Left; Liv, Liver; Lu, Lung;
- 645 M, Male; Mal, Malay; Mat, Maternal; Mo, Mother; O, Older; Ov, Ovarian; Pat, Paternal; PR,
- 646 Progesterone receptor; R, Right; Rec, Rectal; Sis, Sister; Sync, Synchronous; Uni, Unilateral; Y, Younger;
- 647 yr., years.



Figure